Abstract:Abstract Nearly half of human cancers harbor TP53 mutations, which are predominantly through missense mutations that result in accumulation of mutant p53 proteins in cancer cells. More and more findings indicate that the mutant p53 proteins acquire gain-of-function abilities to promote carcinogenesis, metastasis, tumor recurrence and chemoresistance. TP53 mutations are the most frequent genetic alterations in breast cancer, observed in 30% of breast carcinomas, especially the triple-negative breast cancer (TNBC), which most easily metastasizes and confers chemoresistance. Therefore, targeting TP53 mutation in breast cancer might be another promising approach of therapeutics. In this study, the AKT-mTOR dual inhibitor, NVP-BEZ235 (called BEZ235 hereafter) was employed to treat two TNBC cell lines, MDA-MB-231 and MDA-MB-468, which serve as TP53 mutation group at different dosages and time points. The results of CCK8, scratch, Transwell chamber and soft agar tests showed that BEZ235 could inhibit cell growth, migration, invasion and transformation abilities of the above TNBC cells. Most importantly, mutant p53 in these TNBC cells decreased significantly with BEZ235 treatment by Western blot. Therefore, we speculated that BEZ235 might inhibit the metastasis of TNBC cells through mutant p53 decline. Furthermore, we observed the autophagy marker LC3I/II conversion elevated obviously by WB, along with the upregulation of LC3 mRNA, which indicated that autophagy was induced after BEZ235 treatment in TNBC cells. To further understand the relationship of autophagy and p53 decrease upon exposure of BEZ235, autophagy inhibitor 3-MA and lentiviral shRNAs embedding ATG5/ATG7 were applied to deplete autophagy, and we found that mutant p53 was still decreased in the cells treated by NVP235 even though the autophagy was inhibited, which indicated that p53 degradation mediated by NVP235 may not relate with autophagy. In order to explore other potential regulatory mechanisms of the p53 downregulation upon BEZ235 exposure, microRNAs were considered to detect in the TNBC cells after treatment. Interestingly, miR-23a-24a-27a cluster was upregulated about 2-fold in TNBC cells after BEZ235 treatment in our study, while tumor growth and metastasis roles were discovered in some previous findings. More studies need to be done to illustrate miR-23a-24a-27a cluster in the TNBC cells treatment with NVP235, as well as the mechanisms with p53 regulation. In conclusion, our results suggest that BEZ235 might inhibit the metastasis abilities of triple-negative breast cancer cells targeting mutant p53 accumulation, which might provide an important direction to further study the breast cancer harboring mutant p53, and also have promising therapeutic benefits for cancer patients carrying p53 mutations. Citation Format: Jiajing Cai, Jingruo Xia, Dan Xiao, Chang Liu, Hebin Liao, Lei Xu, Dongsheng Wang, Xiaolan Guo. NVP-BEZ235 decreases mutant p53 and affects miR-23a-24a-27a to inhibit metastasis in breast cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3951.

Sensitizing Triple Negative Breast Cancer To Chemotherapy By Mutant-P53-Rescue Drugs.

Actinomycin D Synergizes with Doxorubicin in Triple-Negative Breast Cancer by Inducing P53-dependent Cell Apoptosis.

Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors

Recombinant Dual-target MDM2/MDMX Inhibitor Reverses Doxorubicin Resistance Through Activation of the TAB1/TAK1/p38 MAPK Pathway in Wild-type P53 Multidrug-resistant Breast Cancer Cells

PRIMA-1, a Mutant P53 Reactivator, Restores the Sensitivity of TP53 Mutant-Type Thyroid Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A.

Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53

Abstract 136: Doxorubicin-induced senescence as a mechanism of resistance in TNBC cell lines

Chemotherapy-driven Increases in the CDKN1A/PTN/PTPRZ1 Axis Promote Chemoresistance by Activating the NF-κB Pathway in Breast Cancer Cells.

The PI3K/mTOR dual inhibitor NVP‐BEZ235 stimulates mutant p53 degradation to exert anti‐tumor effects on triple‐negative breast cancer cells

Abstract P49: PROTAC A1874: A Potential Targeted Therapy for Breast Cancer

Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy

Targeting mutant p53 with arsenic trioxide: A preclinical study focusing on triple negative breast cancer

Abstract 4977: Immunogenic Chemotherapy Synergize PD-1 Blockade by Enhancing Dendritic Cells Infiltration in Triple-Negative Breast Cancer (TNBC)

Amplified antitumor efficacy by a targeted drug retention and chemosensitization strategy-based “combo” nanoagent together with PD-L1 blockade in reversing multidrug resistance

Elevated estrogen receptor β expression in triple negative breast cancer cells is associated with sensitivity to doxorubicin by inhibiting the PI3K/AKT/mTOR signaling pathway

Dual-target MDM2/MDMX Inhibitor Increases the Sensitization of Doxorubicin and Inhibits Migration and Invasion Abilities of Triple-Negative Breast Cancer Cells Through Activation of TAB1/TAK1/p38 MAPK Pathway.

Abstract 3951: NVP-BEZ235 Decreases Mutant P53 and Affects Mir-23A-24a-27a to Inhibit Metastasis in Breast Cancer Cells

Triangular Relationship between p53, Autophagy, and Chemotherapy Resistance

APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy

PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway

p53-Induced Autophagy Regulates Chemotherapy and Radiotherapy Resistance in Multidrug Resistance Cancer Cells